Results 31 to 40 of about 121,021 (313)
Pediatric Soft Tissue Sarcomas [PDF]
Surgical Clinics of North America, 2008 Soft tissue sarcomas in children are rare. Approximately 850 to 900 children and adolescents are diagnosed each year with rhabdomyosarcoma (RMS) or a non-RMS soft tissue sarcoma (NRSTS). RMS is more common in children 14 years old and younger and NRSTS in adolescents and young adults.
David M, Loeb +2 more
openaire +2 more sources
Immunotherapy in Soft-Tissue Sarcoma [PDF]
Current Oncology, 2020 Soft-tissue sarcoma (sts) is a rare mesenchymal malignancy that accounts for less than 1% of all adult tumours. Despite the successful advancement of localized therapies such as surgery and radiotherapy, these tumours can, for many, recur—often with metastatic disease.
Ayodele, O., Razak, A.R. Abdul
openaire +2 more sources
Lifestyle Behaviors and Cardiotoxic Treatment Risks in Adult Childhood Cancer Survivors
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Higher doses of anthracyclines and heart‐relevant radiotherapy increase cardiovascular disease (CVD) risk. This study assessed CVD and CVD risk factors among adult childhood cancer survivors (CCSs) across cardiotoxic treatment risk groups and examined associations between lifestyle behaviors and treatment risks.
Ruijie Li +6 more
wiley +1 more source
Nowotwory, 2020 The introduction of immunotherapy with checkpoint inhibitors into clinical practice has radically changed the treatment and prognosis of patients with cancer.
Hanna Koseła-Paterczyk
doaj +1 more source
Retroperitoneal soft tissue sarcoma [PDF]
Cancer, 2005 AbstractThe objective of the current study was to define the optimal treatment for patients with retroperitoneal soft tissue sarcomas (RPS). The authors conducted a review of the pertinent literature and found that the majority of patients had locally advanced RPS at the time of diagnosis.
William M, Mendenhall +5 more
openaire +2 more sources
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Annals of Surgery, 1975 One hundred fifty-five adult patients with "operable" soft part sarcomas including rhabdomyosarcoma, liposarcoma, leiomyosarcoma and fibrosarcoma of the trunk and extremities are reviewed. Local recurrences of 93% and 60% occurred after local and wide excisions of the primary tumor.
R E, Gerner, G E, Moore, J W, Pickren
openaire +3 more sources
Advanced Functional Materials, EarlyView.A 3D disease model is developed using customized hyaluronic‐acid‐based hydrogels supplemented with extracellular matrix (ECM) proteins resembling brain ECM properties. Neurons, astrocytes, and tumor cells are used to mimic the native brain surrounding.
Esra Türker +16 more
wiley +1 more source
Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma
Current OncologyMesenchymal chondrosarcoma (MCS) is characterised by small round cell biology, frequent HEY1-NCOA2 fusion, and high vascularity. These features plausibly lessen extracellular matrix barriers and confer relative chemosensitivity.
Piotr Remiszewski +4 more
doaj +1 more source
Pediatric soft tissue sarcomas [PDF]
CA: A Cancer Journal for Clinicians, 1994 Soft tissue sarcomas are the sixth most common cancer in children and collectively account for about seven percent of all pediatric cancers. The development of increasingly intensive, multimodality treatment protocols for these tumors has led to a steady increase in cure rates for these neoplasms, especially for rhabdomyosarcoma, the most common ...
L H, Wexler, L J, Helman
openaire +2 more sources